Ipsen announces publication of first matching-adjusted indirect comparison of cabometyx® (cabozantinib) versus regorafenib in advanced hepatocellular carcinoma in advances in therapy

Regulatory news: ipsen (euronext: ipn; adr: ipsey) today announced that data from the matching-adjusted indirect comparison (maic) of cabometyx® (cabo

AXDX Ratings Summary

AXDX Quant Ranking